FXR and TGR5 agonists are promising in controlling inflammation in Crohn’s disease and ulcerative colitis (Yoneno et al., 2013; Perino and Schoonjans, 2015; Jia et al., 2018). This evidence concerns the gene GPBAR1 and Crohn disease.